LON:GWP - GW Pharmaceuticals Stock Price, Price Target & More

Previous CloseN/A
Today's RangeN/A
52-Week RangeGBX 211 - GBX 950
VolumeN/A
Average Volume956,721 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About GW Pharmaceuticals (LON:GWP)

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the Company's commercial products. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using its cannabinoid technology platform.

Receive GWP News and Ratings via Email

Sign-up to receive the latest news and ratings for GWP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolLON:GWP
CUSIPN/A
Phone+44-1223-266800

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-819.10%
Return on Equity-51.18%
Return on Assets-44.49%

Miscellaneous

EmployeesN/A
Outstanding Shares302,090,000

How to Become a New Pot Stock Millionaire

GW Pharmaceuticals (LON:GWP) Frequently Asked Questions

What is GW Pharmaceuticals' stock symbol?

GW Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "GWP."

Who are GW Pharmaceuticals' key executives?

GW Pharmaceuticals' management team includes the folowing people:
  • Geoffrey W. Guy, Executive Chairman of the Board
  • Justin Gover, Chief Executive Officer, Director
  • Adam David George, Chief Financial Officer, Company Secretary, Director
  • Christopher John Tovey, Chief Operating Officer, Executive Director
  • Julian S. Gangolli, Executive Director
  • James Julian Noble, Non-Executive Deputy Chairman of the Board, Senior Independent Director
  • Cabot Brown, Non-Executive Independent Director
  • Thomas Gerard Lynch, Non-Executive Independent Director
  • Catherine J. Mackey Ph.D., Non-Executive Independent Director
  • Alicia Secor, Non-Executive Independent Director

Has GW Pharmaceuticals been receiving favorable news coverage?

Media headlines about GWP stock have trended positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. GW Pharmaceuticals earned a news impact score of 0.39 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 47.17 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of GW Pharmaceuticals?

Shares of GWP and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

How can I contact GW Pharmaceuticals?

GW Pharmaceuticals' mailing address is Sovereign House, Vision Park, CAMBRIDGE, 00000, United Kingdom. The biopharmaceutical company can be reached via phone at +44-1223-266800.


MarketBeat Community Rating for GW Pharmaceuticals (GWP)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  64 (Vote Outperform)
Underperform Votes:  57 (Vote Underperform)
Total Votes:  121
MarketBeat's community ratings are surveys of what our community members think about GW Pharmaceuticals and other stocks. Vote "Outperform" if you believe GWP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GWP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

GW Pharmaceuticals (LON:GWP) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/AN/A
Consensus Rating Score: N/AN/AN/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A

GW Pharmaceuticals (LON:GWP) Consensus Price Target History

Price Target History for GW Pharmaceuticals (LON:GWP)

GW Pharmaceuticals (LON:GWP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
9/27/2016Numis SecuritiesReiterated RatingHoldGBX 835View Rating Details
(Data available from 4/26/2016 forward)

Earnings

Dividends

GW Pharmaceuticals (LON:GWP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

GW Pharmaceuticals (LON GWP) Insider Trading and Institutional Ownership History

Insider Trading History for GW Pharmaceuticals (LON:GWP)

GW Pharmaceuticals (LON GWP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/1/2016Tom LynchInsiderSell2,074GBX 790£16,384.60
10/28/2016Geoffrey GuyInsiderSell31,682GBX 790£250,287.80
10/27/2016Geoffrey GuyInsiderSell138,318GBX 804£1,112,076.72
10/26/2016Geoffrey GuyInsiderSell130,000GBX 808£1,050,400
10/25/2016Geoffrey GuyInsiderSell125,000GBX 809£1,011,250
10/24/2016Geoffrey GuyInsiderSell68,900GBX 824£567,736
5/11/2016Guy,GeoffreyInsiderSell300,000GBX 444£1,332,000
5/10/2016Lynch ,TomInsiderSell50,000GBX 441£220,500
3/31/2016Wright,StephenInsiderSell58,200GBX 435£253,170
12/18/2015Guy,GeoffreyInsiderSell6,000GBX 366£21,960
12/10/2015Lynch ,TomInsiderSell4,270GBX 451£19,257.70
6/12/2015James NobleInsiderSell20,000GBX 636£127,200
6/11/2015Stephen WrightInsiderSell170,400GBX 641£1,092,264
2/9/2015Christopher John ToveyInsiderSell10,000GBX 404.20£40,420
(Data available from 1/1/2013 forward)

Headlines

GW Pharmaceuticals (LON GWP) News Headlines

Source:
DateHeadline
What to expect from marijuana stocks after the first big medical cannabis winWhat to expect from marijuana stocks after the first big medical cannabis win
finance.yahoo.com - April 24 at 4:18 PM
Here’s Why The Committee News Is So Important For GW PharmaceuticalsHere’s Why The Committee News Is So Important For GW Pharmaceuticals
finance.yahoo.com - April 23 at 4:07 PM
The Only 4 States That Completely Ban THC and CBDThe Only 4 States That Completely Ban THC and CBD
finance.yahoo.com - April 22 at 4:46 PM
Philip Morris International Inc. Stock Went Up in Smoke — Go LongPhilip Morris International Inc. Stock Went Up in Smoke — Go Long
finance.yahoo.com - April 20 at 4:10 PM
The Market In 5 Minutes: Oil, Amazon, GW Pharma And MoreThe Market In 5 Minutes: Oil, Amazon, GW Pharma And More
finance.yahoo.com - April 20 at 4:10 PM
FDA Panel Votes To Approve Marijuana-Based Drug For EpilepsyFDA Panel Votes To Approve Marijuana-Based Drug For Epilepsy
finance.yahoo.com - April 19 at 4:18 PM
FDA Panel Backs Cannabis-Based Drug For Childhood SeizuresFDA Panel Backs Cannabis-Based Drug For Childhood Seizures
finance.yahoo.com - April 19 at 4:18 PM
3 "Marijuana Firsts" You Should Expect in 20183 "Marijuana Firsts" You Should Expect in 2018
finance.yahoo.com - April 19 at 9:55 AM
Want to Buy Marijuana Stocks? Check Out These 3 ChartsWant to Buy Marijuana Stocks? Check Out These 3 Charts
finance.yahoo.com - April 18 at 4:19 PM
Today’s Research Reports on Trending Tickers: GW Pharmaceuticals and Arena PharmaceuticalsToday’s Research Reports on Trending Tickers: GW Pharmaceuticals and Arena Pharmaceuticals
finance.yahoo.com - April 18 at 9:56 AM
Is Cannabis The Answer To Seizures? These Biotechs Say YesIs Cannabis The Answer To Seizures? These Biotechs Say Yes
finance.yahoo.com - April 13 at 10:24 AM
BRIEF-GW Pharmaceuticals Announces Receipt Of Notices Of Allowance By USPTOBRIEF-GW Pharmaceuticals Announces Receipt Of Notices Of Allowance By USPTO
www.reuters.com - March 15 at 9:50 AM
GW Pharmaceuticals Announces Receipt of Notices of Allowance by the United States Patent and Trademark Office (USPTO) for Five New Epidiolex® (cannabidiol) PatentsGW Pharmaceuticals Announces Receipt of Notices of Allowance by the United States Patent and Trademark Office (USPTO) for Five New Epidiolex® (cannabidiol) Patents
finance.yahoo.com - March 13 at 5:55 PM
GW Pharmaceuticals Announces Preliminary Results of Phase 2a Study for its Pipeline Compound GWP42006GW Pharmaceuticals Announces Preliminary Results of Phase 2a Study for its Pipeline Compound GWP42006
finance.yahoo.com - February 21 at 4:21 PM
Today’s Research Reports on Trending Tickers: GW Pharmaceuticals and Scotts Miracle-GroToday’s Research Reports on Trending Tickers: GW Pharmaceuticals and Scotts Miracle-Gro
finance.yahoo.com - February 6 at 8:50 AM
GW Pharmaceuticals PLC – ADR (GWPH) Garners EMA Cannabidiol ApprovalGW Pharmaceuticals PLC – ADR (GWPH) Garners EMA Cannabidiol Approval
investorplace.com - February 5 at 6:36 PM
GW Pharmaceuticals plc Reports Fiscal First Quarter 2018 Financial Results and Operational ProgressGW Pharmaceuticals plc Reports Fiscal First Quarter 2018 Financial Results and Operational Progress
finance.yahoo.com - February 5 at 4:41 PM
GW Pharmaceuticals Announces the European Medicines Agency (EMA) Accepts Epidiolex® (cannabidiol) Marketing Authorization Application (MAA) for ReviewGW Pharmaceuticals Announces the European Medicines Agency (EMA) Accepts Epidiolex® (cannabidiol) Marketing Authorization Application (MAA) for Review
finance.yahoo.com - February 5 at 4:41 PM
Today’s Research Reports on Trending Tickers: GW Pharmaceuticals and Intercept PharmaceuticalsToday’s Research Reports on Trending Tickers: GW Pharmaceuticals and Intercept Pharmaceuticals
finance.yahoo.com - February 2 at 8:51 AM
GW Pharmaceuticals to Report Q1 Financial Results and Host Conference Call on 5 February, 2018GW Pharmaceuticals to Report Q1 Financial Results and Host Conference Call on 5 February, 2018
feeds.benzinga.com - January 29 at 1:54 PM
GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Announce Publication of Landmark Epidiolex® (cannabidiol) Study in The LancetGW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Announce Publication of Landmark Epidiolex® (cannabidiol) Study in The Lancet
finance.yahoo.com - January 25 at 8:49 AM
What Stocks are on the Marijuana Index?What Stocks are on the Marijuana Index?
finance.yahoo.com - January 3 at 11:14 AM
GW Pharmaceuticals Submits Marketing Authorisation Application in Europe for Epidiolex® (cannabidiol) in the treatment of Lennox-Gastaut syndrome and Dravet syndromeGW Pharmaceuticals Submits Marketing Authorisation Application in Europe for Epidiolex® (cannabidiol) in the treatment of Lennox-Gastaut syndrome and Dravet syndrome
finance.yahoo.com - December 29 at 8:51 AM
GW Pharmaceuticals reicht europäischen Antrag auf Marktzulassung für Epidiolex® (Cannabidiol) zur Behandlung von Lennox-Gastaut-Syndrom und Dravet-Syndrom einGW Pharmaceuticals reicht europäischen Antrag auf Marktzulassung für Epidiolex® (Cannabidiol) zur Behandlung von Lennox-Gastaut-Syndrom und Dravet-Syndrom ein
www.prnewswire.com - December 29 at 7:52 AM
GW Pharmaceuticals dépose une demande dautorisation de mise sur le marché pour Epidiolex® (cannabidiol) dans le traitement du syndrome de Lennox-Gastaut et du syndrome de DravetGW Pharmaceuticals dépose une demande d'autorisation de mise sur le marché pour Epidiolex® (cannabidiol) dans le traitement du syndrome de Lennox-Gastaut et du syndrome de Dravet
www.prnewswire.com - December 29 at 7:52 AM
GW Pharmaceuticals Announces the Appointment of Three New Independent Members to its Board of DirectorsGW Pharmaceuticals Announces the Appointment of Three New Independent Members to its Board of Directors
finance.yahoo.com - December 21 at 7:03 AM
Alternate Health Begins Beta Testing of FlorPass Patient Management Software System in Key MarketAlternate Health Begins Beta Testing of FlorPass Patient Management Software System in Key Market
finance.yahoo.com - December 18 at 3:21 PM
UK Stocks-Factors to watch on Dec 4UK Stocks-Factors to watch on Dec 4
www.reuters.com - December 4 at 7:12 AM
GW Pharmaceuticals plc Reports Fiscal Fourth Quarter 2017 and Year-End Financial Results and Operational ProgressGW Pharmaceuticals plc Reports Fiscal Fourth Quarter 2017 and Year-End Financial Results and Operational Progress
finance.yahoo.com - December 4 at 7:12 AM
GW Pharmaceuticals to Report Q4 and Year-End Financial Results and Host Conference Call on 4 December, 2017GW Pharmaceuticals to Report Q4 and Year-End Financial Results and Host Conference Call on 4 December, 2017
finance.yahoo.com - November 27 at 5:35 PM
Todays Research Reports on Stocks to Watch: GW Pharmaceuticals and Zogenix Inc.Today's Research Reports on Stocks to Watch: GW Pharmaceuticals and Zogenix Inc.
finance.yahoo.com - October 2 at 1:49 PM
Todays Research Reports on Stocks to Watch: Moleculin Biotech Inc. and GW Pharmaceuticals PLCToday's Research Reports on Stocks to Watch: Moleculin Biotech Inc. and GW Pharmaceuticals PLC
finance.yahoo.com - August 31 at 5:06 AM
Zynerba Pharma’s failed cannabidiol gel trial has upside for rival GW PharmaZynerba Pharma’s failed cannabidiol gel trial has upside for rival GW Pharma
finance.yahoo.com - August 15 at 5:41 AM
Better Buy: Cara Therapeutics Inc. vs. GW Pharmaceuticals plcBetter Buy: Cara Therapeutics Inc. vs. GW Pharmaceuticals plc
www.fool.com - July 30 at 9:27 AM
GW Pharmaceuticals to Report Q3 Financial Results  and Host Conference Call on 7 August, 2017GW Pharmaceuticals to Report Q3 Financial Results and Host Conference Call on 7 August, 2017
feeds.benzinga.com - July 24 at 4:21 PM
Marijuana Stocks on The Rebound in July 2017Marijuana Stocks on The Rebound in July 2017
finance.yahoo.com - July 12 at 8:02 PM
UK Stocks-Factors to watch on May 10 - ReutersUK Stocks-Factors to watch on May 10 - Reuters
www.reuters.com - May 10 at 10:47 PM
GW Pharmaceuticals to Report Q2 Financial Results  and Host Conference Call on 9 May, 2017GW Pharmaceuticals to Report Q2 Financial Results and Host Conference Call on 9 May, 2017
feeds.benzinga.com - May 2 at 10:40 AM
10 Reasons Your Marijuana Stock Is a Terrible Investment10 Reasons Your Marijuana Stock Is a Terrible Investment
www.fool.com - February 27 at 6:59 PM
Could Marijuana Be the Next Miracle Drug for Treating Cancer?Could Marijuana Be the Next Miracle Drug for Treating Cancer?
www.fool.com - February 20 at 10:53 AM
GW Pharmaceuticals Is Set to Benefit as Cannabis Takes on CancerGW Pharmaceuticals Is Set to Benefit as Cannabis Takes on Cancer
www.thestreet.com - February 9 at 6:25 PM
GW Pharmaceuticals to Report Q1 Financial Results and Host Conference Call on 7 February, 2017GW Pharmaceuticals to Report Q1 Financial Results and Host Conference Call on 7 February, 2017
feeds.benzinga.com - January 30 at 8:12 AM
3 Big Risks for Marijuana Stocks in 20173 Big Risks for Marijuana Stocks in 2017
www.fool.com - January 23 at 4:00 PM
GW Pharma Cannabinoid Pipeline Undervalued By The Market - Seeking AlphaGW Pharma Cannabinoid Pipeline Undervalued By The Market - Seeking Alpha
seekingalpha.com - December 14 at 6:16 PM
This Marijuana Stocks Sales Are Shrinking: Should We Care?This Marijuana Stock's Sales Are Shrinking: Should We Care?
www.fool.com - December 6 at 10:38 AM
GW Pharmaceuticals plc Announces Epidiolex® (cannabidiol) Data ... - GlobeNewswire (press release)GW Pharmaceuticals plc Announces Epidiolex® (cannabidiol) Data ... - GlobeNewswire (press release)
globenewswire.com - December 1 at 10:44 AM
Notice of Q4 and year-end results - London South East (registration) (blog)Notice of Q4 and year-end results - London South East (registration) (blog)
www.lse.co.uk - November 30 at 10:42 PM
3 Healthcare Stocks Investors Have Been Thankful for This Year3 Healthcare Stocks Investors Have Been Thankful for This Year
www.fool.com - November 29 at 4:53 PM
3 Healthcare Stocks Investors Have Been Thankful for This Year3 Healthcare Stocks Investors Have Been Thankful for This Year
www.fool.com - November 29 at 4:53 PM
Why this Marijuana Stock Was a Top Stock So Far in 2016Why this Marijuana Stock Was a Top Stock So Far in 2016
www.fool.com - November 29 at 4:53 PM

SEC Filings

GW Pharmaceuticals (LON:GWP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

GW Pharmaceuticals (LON GWP) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.